[EN] FLAVONOID DIMERS AND THEIR USE<br/>[FR] DIMÈRES FLAVONOÏDES ET LEURS APPLICATIONS
申请人:UNIV MCGILL
公开号:WO2011137516A1
公开(公告)日:2011-11-10
This invention relates to bis-flavonoid compounds of formula Flavonoid-Linker-Y-Linker-Flavonoid, their synthesis and use for inhibiting multidrug resistance in chemotherapy and protozoan infection.
Amine Linked Flavonoid Dimers as Modulators for P-Glycoprotein-Based Multidrug Resistance: Structure–Activity Relationship and Mechanism of Modulation
作者:Kin-Fai Chan、Iris L. K. Wong、Jason W. Y. Kan、Clare S. W. Yan、Larry M. C. Chow、Tak Hang Chan
DOI:10.1021/jm201121b
日期:2012.3.8
Here we report a great improvement in reversal potency of cancer drug resistance when flavonoid dimers possess a functionally substituted aminopolyethylene glycol linker. The most potent compound, 18, contains a N-benzyl group at the linker. It has many advantages including (1) high potencies in reversing P-glycoprotein (P-gp) mediated resistance in LCC6MDR cells to various anticancer drugs with EC50 in the nanomolar range, (2) low toxicity and high therapeutic index, and (3) preferential inhibition of P-gp over multidrug resistance protein 1 and breast cancer resistance protein. Compound 18 stimulates P-gp-ATPase activity by 2.7-fold and mediates a dose-dependent inhibition of doxorubicin (DOX) transport activity. Lineweaver-Burk and Dixon plots suggest that 18 is a competitive inhibitor to DOX in binding to P-gp with a K-i of 0.28-0.34 mu M and a Hill coefficient of 1.17. Moreover, the LCC6MDR cell displays about 2.1-fold lower intracellular accumulation of 18 compared to the wild type, suggesting that 18 is a P-gp substrate as well.
FLAVONOID DIMERS AND THEIR USE
申请人:Chan Tak-Hang
公开号:US20130045935A1
公开(公告)日:2013-02-21
This invention relates to bis-flavonoid compounds of formula
Flavonoid-Linker-Y-Linker-Flavonoid,
their synthesis and use for inhibiting multidrug resistance in chemotherapy and protozoan infection.
TETRAMALEIMIDE LINKERS AND USE THEREOF
申请人:NewBio Therapeutics, Inc.
公开号:US20210128668A1
公开(公告)日:2021-05-06
The present invention is directed to tetramaleimide linkers and use thereof, more specifically to the compounds represented by formula I and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from the tetramaleimide linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I is the same as that in the description.